Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.
The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.
Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.
Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.
Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.
Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.
Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.
Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.
US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.
Researchers believe arsenic exposure might contribute to higher-than-normal rates of bladder cancer in the region.
Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.
Older patients who undergo surgery to treat cancer are more likely to experience injuries and other health issues such as falling down, breaking bones, dehydration, bed sores, failure to thrive, and delirium. The risks are particularly notable in patients who undergo major abdominal surgery.
Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.
Mental health status prior to bladder cancer surgery may be associated with postoperative outcomes.
Researchers identified potential genetic alterations in penile cancer that could lead to targeted treatments for the disease. A complex landscape that could suggest clinical trials of targeted therapies was described in a recent report.
Taking muscle-building supplements significantly increases likelihood of developing testicular cancer.
The addition of chemotherapy after bladder cancer surgery lowered risk of death by approximately 30%, over surgery alone, according to a study that reviewed patient data.
Older white males with advanced bladder cancer are the most likely to commit suicide among patients with genitourinary cancers.
Risk factors for suicide include male gender, distant disease, increasing age, race/ethnicity.
Women with hematuria were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new study.
A new study found that most women who undergo conservative surgery for vulvar cancer experience little to no long-term disruption to sexuality and body image.
The severity of acute urinary symptoms in patients who underwent radiotherapy for early prostate cancer can be predicted by using a modeling program together with the IPSS and dosage measure. These findings were presented at the 5th European Multidisciplinary Meeting on Urological Cancers.
Bladder cancer characterized by mutations of the STAG2 gene appears to be less likely to recur than bladder cancer with no such mutations, researchers have discovered.
Sulfasalazine, which is commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area.
A gene that helps regulate bladder cancer growth and metastasis appears to be a promising target for detecting and monitoring the disease.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|